Nanoscope Therapeutics has reported data from a mid-stage clinical trial that suggests its optogenetic ... is an effective treatment for incurable eye disease retinitis pigmentosa (RP).

Since its early days in the mid-2000s, optogenetics, with its potential ... that patients who were blind or nearly blind from retinitis pigmentosa could detect light and motion following treatment.

Therapeutic optogenetic therapy for vision restoration certainly ... That’s how you’re reading the words on this page right ...

Two-year data with eyeDNA Therapeutics’ gene therapy for retinitis pigmentosa (RP), an inherited form of blindness, has prompted the biotech to seek discussions with regulators about the design ...

New studies in rats suggest the drug reserpine, approved in 1955 for high blood pressure, might treat the blinding disease retinitis pigmentosa.

Researchers have successfully developed a novel drug to restore vision. The treatment method restores vision through retinal nerve regeneration.

"We are excited by the therapeutic benefits seen in retinitis pigmentosa ... pivotal milestone in the treatment of inherited retinal degenerations, demonstrating that optogenetics can successfully ...

LUXTURNA (voretigene neparvovec-rzyl, AAV2-hRPE65v2) is a one-time gene therapy designed to treat ... by Leber's congenital amaurosis or retinitis pigmentosa due to confirmed biallelic RPE65 ...

Optogenetics offers a ... four blind retinitis pigmentosa patients with ABCA4 variants received a single intravitreal gene therapy injection. Noninvasive imaging confirmed retinal gene expression ...